Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine

Pharmacological Reviews

Volumn 60, Issue 4, 2008, Pages 513-535

  Rosskopf, Dieter ^a   Michel, Martin C ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; AZEPEXOLE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; METHOXAMINE; METHYLERGOMETRINE; METOPROLOL; MUSCARINIC RECEPTOR; PROPRANOLOL; TERBUTALINE; TIMOLOL; VASOPRESSIN RECEPTOR;

ALPHA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

CARDIOVASCULAR DISEASES; HUMANS; LIGANDS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 58149091781     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.108.000612     Document Type: Review

References (219)

1. Abe M, Nakura J, Yamamoto M, Jin JJ, Wu Z, Tabara Y, Yamamoto Y, Igase M, Kohara K, and Miki T (2002) Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 40:261-265.
2. Agerholm-Larsen B, Nordestgaard BG, and Tybjaerg-Hansen A (2000) ACE gene polymorphisms in cardiovascular disease: metaanalysis of small and large studies in whites. Arterioscler Thromb Vasc Biol 20:484-492.
3. ALLHAT Officers (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 283:1967-1975.
4. 3-adrenoceptor agonists on pharmacology, physiology and obesity drug discovery. Naunyn Schmiedebergs Arch Pharmacol 378:225-240.
5. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, and Eckfeldt JH (2005) Pharmacogenetic association of the angiotensinconverting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment. The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111:3374-3383.
6. Bagos PG, Elefsinioti AL, Nikolopoulos GK, and Hamodrakas SJ (2007) The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14094 cases and 17760 controls. J Hypertens 25:487-500.
7. Barbato E, Penicka M, Delrue L, Van Durme F, De Bruyne B, Goethals M, Wijns W, Vanderheyden M, and Bartunek J (2007) Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart 93:856-861.
8. Barendrecht MM, Oelke M, Laguna MP, and Michel MC (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749-752.
9. Baumgart D, Naber C, Haude M, Oldenburg O, Erbel R, Heusch G, and Siffert W (1999) G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Circ Res 85:965-969.
10. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, and Johnson JA (2006) Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics. Pharmacogenomics J 6:174-178.
11. Belfer I, Buzas B, Evans C, Hipp H, Phillips G, Taubman J, Lorincz I, Lipsky RH, Enoch MA, Max MB, et al. (2005) Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 13:341-351.
12. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P, Poirier O, Topouchian J, and Asmar R (1996) Influence of the angiotensin II type 1 receptor gene polymorphism on the effect of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 28:1081-1084.
13. Bernstein KE, Xiao HD, Frenzel K, Li P, Shen XZ, Adams JW, and Fuchs S (2005) Six truisms concerning ACE and the renin-angiotensin-system educed from the genetic analysis of mice. Circ Res 96:1135-1144.
14. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, Lumley T, and Rosendaal FR (2003) Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 16:1011-1017.
15. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, Kingma JH, Witteman JC, and Stricker BH (2005) Mortality in patients with hypertension on angiotensin-1 converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 15:75-81.
16. Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, Lalic N, and Walker M, and European Group for the Study of Insulin Resistance Relationship Between Insulin Sensitivity and Cardiovascular Disease Risk Study Group (2008) Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care 31:789-794.
17. Brodde OE (2007) β-Adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s) - adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374:361-372.
18. Brodde OE (2008) β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 117:1-29.
19. Brodde OE and Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651-690.
20. 2-adrenergic receptor down-regulation. Clin Pharmacol Ther 74:255-263.
21. 2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am J Physiol Heart Circ Physiol 285:H2034-H2038.
22. 2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics 13:59-66.
23. Bruck H, Leineweber K, Park J, Weber M, Heusch G, Philipp T, and Brodde OE (2005) Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 78:232-238.
24. 1B-adrenergic receptor polymorphisms. J Pharmacol Exp Ther 291:793-798.
25. 1-adrenoceptor polymorphism in humans. Pharmacogenetics 11:199-205.
26. Büscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, Insel PA, and Ratjen F (2002) β2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 12:347-353.
27. Büscher R and Grasemann H (2006) Disease-modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn-Schmiedebergs Arch Pharmacol 374:65-77.
28. Bylund DB, Ray-Prenger C, and Murphy TJ (1988) Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 245:600-607.
29. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, and Trendelenburg U (1994) IV. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev 46:121-136.
30. Canham RM, Das SR, Leonard D, Abdullah SM, Mehta SK, Chung AK, Li JL, Victor RG, Auchus RJ, and Drazner MH (2007) Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. J Am Coll Cardiol 49:274-276.
31. 2B-adrenergic receptor gene. Biochem Pharmacol 67:469-478.
32. Chen Y, Nakura J, Jin JJ, Wu Z, Yamamoto M, Abe M, Tabara Y, Yamamoto Y, Igase M, Bo X, et al. (2003) Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption. Hypertens Res 26:439-444.
33. Chen L, Meyers D, Javorsky G, Burstow D, Lolekha P, Lucas M, Semmler AB, Savarimuthu SM, Fong KM, Yang IA, et al. (2007) Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 17:941-949.
34. 2-adrenoceptor on desensitisation in human lung mast cells. Pharmacogenetics 10:153-162.
35. Cicoira M, Rossi A, Bonapace S, Zanolla L, Perrot A, Francis DP, Golia G, Franceschini L, Osterziel KJ, and Zardini P (2004) Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med 116:657-661.
36. 2-Adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36:371-375.
37. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027.
38. Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, and Severens JL (2007) Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 17:359-368.
39. Coto E, Marín R, Alvarez V, Praga M, Fernández Andrade C, Arias M, Poveda R, Vallés M, Galcerán JM, Luño J, et al. (2005) Pharmacogenetics of angiotensin system in non diabetic nephropathy. Nefrologia 25:381-386.
40. Cvetković RS and Plosker GL (2005) Desmopressin in adults with nocturia. Drugs 65:99-107; discussion 108-109.
41. de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, Foucher-Hossein C, Amouyel P, Dallongeville J, and Bauters C (2005) Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15:137-142.
42. 2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345:1030-1035.
43. Dishy V, Landau R, Sofowora GG, Xie HG, Smiley RM, Kim RB, Byrne DW, Wood AJ, and Stein CM (2004) Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 14:517-522.
44. Drake KA, Galanter JM, and Burchard EG (2008) Race, ethnicity and social class and the complex etiologies of asthma. Pharmacogenomics 9:453-462.
45. Dudley C, Keavney B, Casadei B, Conway J, Bird R, and Ratcliffe P (1996) Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of the renin-angiotensin system genes. J Hypertens 14:259-262.
46. Duster T (2007) Medicalisation of race. Lancet 369:702-704.
47. Eichelbaum M, Spannbrucker N, Steincke B, and Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187.
48. Eichelbaum M, Ingelman-Sundberg M, and Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119-137.
49. Etzel JP, Rana BK, Wen G, Parmer RJ, Schork NJ, O'Connor DT, and Insel PA (2005) Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Hypertension 45:1207-1213.
50. Fenech AG, Billington CK, Swan C, Richards S, Hunter T, Ebejer MJ, Felice AE, Ellul-Micallef R, and Hall IP (2004) Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol 30:678-686.
51. 3 receptor genes in normal and asthmatic subjects. Br J Pharmacol 133:43-48.
52. Feng Y, Niu T, Xu X, Chen C, Li Q, Qian R, Wang G, and Xu X (2002) Insertion/ deletion polymorphism of the ACE gene is associated with type 2 diabetes. Diabetes 51:1986-1988.
53. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, and Glorioso N (2004) Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade. Pharmacogenomics J 4:154-160.
54. Franconi F, Brunelleschi S, Steardo L, and Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55:81-95.
55. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, et al. (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889-894.
56. 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens 8:863-869.
57. Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, Jöckel KH, Siffert W, and Schmid KW (2005) GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 11:5071-5077.
58. Frey UH, Lümmen G, Jäger T, Jöckel KH, Schmid KW, Rübben H, Müller N, Siffert W, and Eisenhardt A (2006) The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 12:759-763.
59. Frey UH, Hauner H, Jöckel KH, Manthey I, Brockmeyer N, and Siffert W (2008) A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. Pharmacogenet Genomics 18:141-151.
60. 2-Adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol 546:583-589.
61. Goedde HW, Schoepf E, and Fleischmann D (1964) Studies on pharmacogenetics. I. The enzymic acetylation of isonicotinic acid hydrazide (INH). Biochem Pharmacol 13:1671-1675.
62. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446.
63. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, Luft FC, Hoehe MR, and Skrabal F (1999) β-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33:1425-1430.
64. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414-9419.
65. Gu D, Ge D, Snieder H, He J, Chen S, Huang J, Li B, Chen R, and Qiang B (2006) Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension. J Hypertens 24:1049-1056.
66. Guimarães S and Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319-356.
67. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, Parving HH, Cambien F, Tregouet DA, Gut IG, et al.; EURAGEDIC (European Rational Approach for Genetics of Diabetic Complications) Study Group (2007) Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 18:1284-1291.
68. 2- adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? J Hypertens 24:1003-1007.
69. Haiman CA, Henderson SO, Bretsky P, Kolonel LN, and Henderson BE (2003) Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res 63:6984-6987.
70. Hansen JL, Haunsø S, Brann MR, Sheikh SP, and Weiner DM (2004) Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor. Mol Pharmacol 65:770-777.
71. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, Colman S, Leguennec S, MacMahon S, et al. (2003) The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42:297-303.
72. Hauner H, Meier M, Jöckel KH, Frey UH, and Siffert W (2003) Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 13:453-459.
73. Hautala AJ, Rankinen T, Kiviniemi AM, Mäkikallio TH, Huikuri HV, Bouchard C, and Tulppo MP (2006) Heart rate recovery after maximal exercise is associated with acetylcholine receptor M2 (CHRM2) gene polymorphism. Am J Physiol Heart Circ Physiol 291:H459-H466.
74. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters SP, Weiss ST, and Bleecker ER (2006) Sequence, haplotype, and association analysis of ADRβ2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174:1101-1109.
75. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, et al. (2008) The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 40:217-224.
76. Hendriks-Balk MC, Peters SL, Michel MC, and Alewijnse AE (2008) Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. Eur J Pharmacol 585:278-291.
77. 2-Adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 13:1021-1026.
78. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, and Brown MJ (1995) Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 13:1602-1609.
79. 2 adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Br J Pharmacol 133:708-712.
80. 2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 139:537-542.
81. Huang K, Shi Y, Tang W, Tang R, Guo S, Xu Y, Meng J, Li X, Feng G, and He L (2008) No association found between the promotor variants of ADRA1A and schizophrenia in the Chinese population. J Psychiatr Res 42:384-388.
82. Ingelman-Sundberg M, Sim SC, Gomez A, and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
83. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, et al. (1997) A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797.
84. Insel PA, Tang CM, Hahntow I, and Michel MC (2007) Impact of GPCRs in clinical medicine: genetic variants and drug targets. Biochim Biophys Acta 1768:994-1005.
85. Ismail R and Teh LK (2006) The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 31:99-109.
86. sα gene with essential hypertension and response to β-blockade. Hypertension 34:8-14.
87. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, and Lalouel JM (1992) Molecular basis for human hypertension: role of angiotensinogen. Cell 71:169-180.
88. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74:44-52.
89. Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, and Melhus H (2004) Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 27:347-350.
90. 2-adrenoceptor on the effects of β-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol 3:91-95.
91. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, and Holst D (2003) Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13:379-382.
92. 2- adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther 77:388-403.
93. Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, and Brockmöller J (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 76:302-312.
94. Kirstein SL and Insel PA (2004) Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 56:31-52.
95. Koopmans RP, Insel PA, and Michel MC (2003) Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics 13:705-713.
96. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, and Lind L (2001) Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 19:1783-1787.
97. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, and Lind L (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 20:657-663.
98. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, and Lind L (2004) Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Am J Hypertens 17:8-13.
99. Kurnik D, Muszkat M, Friedman EA, Sofowora GG, Diedrich A, Xie HG, Harris PA, Choi L, Wood AJ, and Stein CM (2007) Effect of the alpha2C-adrenoreceptor deletion 322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects. J Hypertens 25:763-771.
100. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, Dupont WD, Scheinin M, Wood AJ, and Stein CM (2008a) Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension 51:406-411.
101. Kurnik D, Friedman EA, Muszkat M, Sofowora GG, Xie HG, Dupont WD, Wood AJ, and Stein CM (2008b) Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. Pharmacogenet Genomics 18:743-750.
102. Kuznetsova T, Staessen JA, Stolarz K, Ryabikov A, Tikhonoff V, Olszanecka A, Bianchi G, Brand E, Casiglia E, Dominiczak A, et al.; and European Project On Genes in Hypertension (EPOGH) Investigators (2004) Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake. J Hypertens 22:287-295.
103. Large V, Hellström L, Reynisdottir S, Lönnqvist F, Eriksson P, Lannfelt L, and Arner P (1997) Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered beta-2 adrenoceptor function. J Clin Invest 100:3005-3013.
104. 1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol 371:229-239.
105. 1-adrenoceptor polymorphism. Naunyn Schmiedebergs Arch Pharmacol 375:303-309.
106. Leineweber K, Büscher R, Bruck H, and Brodde OE (2004) β-Adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:1-22.
107. Levin MC, Marullo S, Muntaner O, Andersson B, and Magnusson Y (2002) The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435.
108. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103:11288-11293.
109. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, et al. (2008) A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517.
110. Liljedahl U, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L, and Kurland L (2004) Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens 22:2321-2328.
111. 2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. J Asthma 43:185-191.
112. 2- adrenoceptors in asthmatic patients. Chest 115:324-328.
113. 1-adrenergic receptor is associated with the carviovascular response to metoprolol. Clin Pharmacol Ther 74:372-379.
114. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, et al. (2007) Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 17:277-282.
115. Lu Y, Zhu H, Wang X, Snieder H, Huang Y, Harshfield GA, Treiber FA, and Dong Y (2006) Effects of dopamine receptor type 1 and Gs protein alpha subunit gene polymorphisms on blood pressure at rest and in response to stress. Am J Hypertens 19:832-836.
116. Maack C, Cremers B, Flesch M, Höper A, Südkamp M, and Böhm M (2000) Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 130:1131-1139.
117. Mahgoub A, Idle JR, Dring LG, Lancaster R, and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
118. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, and Alhenc-Gelas F (1994) Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388.
119. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, Feldman DS, Schmittgen TD, and Elton TS (2007) The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA -155 binding. J Biol Chem 282:24262-24269.
120. 1- adrenergic receptor. J Biol Chem 274:12670-12674.
121. McNamara DM (2008) Emerging role of pharmacogenomics in heart failure. Curr Opin Cardiol 23:261-268.
122. Meirhaeghe A, Bauters C, Helbecque N, Hamon M, McFadden E, Lablanche JM, Bertrand M, and Amouyel P (2001) The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction. Eur Heart J 22:845-848.
123. Mellen PB and Herrington DM (2005) Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 23:1311-1325.
124. Meng Y, Baldwin CT, Bowirrat A, Waraska K, Inzelberg R, Friedland RP, and Farrer LA (2006) Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. Am J Hum Genet 78:871-877.
125. Messerli FH, Bangalore S, and Julius S (2008) Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117:2706-2715; discussion 2715.
126. Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, Donato F, Nardi G, and Dei Cas L (2006) Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur J Heart Fail 8:131-135.
127. 1-adrenergic polymorphisms confer differential function and predisposition to heart failure. Nature Med 9:1300-1305.
128. Michel MC and Alewijnse AE (2007) Ligand-directed signaling: 50 ways to find a lover. Mol Pharmacol 72:1097-1099.
129. 2-Adrenergic receptor gene polymorphisms - will the important one please step forward? J Am Coll Cardiol 52:1389-1390.
130. Michel MC and Parra S (2008) Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 378:217-224.
131. 2A-adrenoceptor gene polymorphism in the HANE study. Nephrol Dial Transplant 14:2657-2663.
132. Miller JA, Thai K, and Scholey JW (1999) Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 56: 2173-2180.
133. Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M, and Emanuele E (2006) The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397:159-163.
134. Mitchell A, Lückebergfeld B, Bührmann S, Rushentsova U, Nürnberger J, Siffert W, Schäfers RF, Philipp T, and Wenzel RR (2004) Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism. Clin Pharmacol Ther 76:396-408.
135. Mitchell A, Rushentsova U, Siffert W, Philipp T, and Wenzel RR (2006) The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β3 subunit (GNB3) C825T polymorphism. Clin Pharmacol Ther 79:274-281.
136. 1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. BJU Int 97:852-855.
137. 1-adrenergic receptor poylmorphisms in human right atrium in vitro. J Am Coll Cardiol 40:1275-1282.
138. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, and Lenz T (1998) Contribution of angiotensin I converting enzyme gene polymorphisms and angiotensinogen polymorphisms to blood pressure regulation in essential hypertension. Am J Hypertens 11:174-183.
139. 1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 14:271.
140. 2-adrenergic receptor gene and desensitization in human airways smooth muscle. Am J Respir Crit Care Med 162:2117-2124.
141. Moore CA, Milano SK, and Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451-482.
142. Morgan T, Craven C, Nelson L, Lalouel JM, and Ward K (1997) Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest 100:1406-1415.
143. 2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genomics 15:407-414.
144. Narita I, Goto S, Saito N, Song J, Omori K, Kondo D, Sakatsume M, and Gejyo F (2003) Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism. J Med Genet 40:e130.
145. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, Alim T, Bonne O, Luckenbaugh DA, Manji H, et al. (2005) Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 15:143-149.
146. Ng DP, Tai BC, Koh D, Tan KW, and Chia KS (2005) Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48:1008-1016.
147. Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimäki T, and Kähönen M (2005) Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 61:811-819.
148. Niu T, Chen X, and Xu X (2002) Angiotensin converting enzyme gene insertion/ deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 62:977-993.
149. 1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 60:414-417.
150. Nonen S, Okamoto H, Fujio Y, Takemoto Y, Yoshiyama M, Hamaguchi T, Matsui Y, Yoshikawa J, Kitabatake A, and Azuma J (2008) Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J 8:78-84.
151. Nürnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gössl M, Philipp T, Michel MC, and Schäfers RF (2003) Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 74:53-60.
152. Oro C, Qian H, and Thomas WG (2007) Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 113:210-226.
153. 1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 99:233-238.
154. Pacanowski M, Gong Y, Cooper-Dehoff R, Schork N, Shriver M, Langaee T, Pepine C, and Johnson JA (2008) Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther, doi: 10.1038/clpt.2008.139.
155. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, Hattersley AT, Morris AD, and Palmer CN (2007) Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56:2178-2182.
156. Postma DS, Kerstjens HA, and ten Hacken NH (2008) Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol 378:203-215.
157. Premont RT and Gainetdinov RR (2007) Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69:511-534.
158. Rahemtulla T and Bhopal R (2005) Pharmacogenetics and ethnically targeted therapies. BMJ 330:1036-1037.
159. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39:155-160.
160. Ravn LS, Benn M, Nordestgaard BG, Sethi AA, Agerholm-Larsen B, Jensen GB, and Tybjaerg-Hansen A (2008) Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet Genomics 18:525-533.
161. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117:229-235.
162. Rossi GP and Pitter G (2006) Genetic variation in the endothelin system. Do polymorphisms affect the therapeutic strategies? Ann N Y Acad Sci 1069:34-50.
163. Rosskopf D, Manthey I, Habich C, Kielbik M, Eisenhardt A, Nikula C, Urban M, Kohnen S, Graf E, Ravens U, et al. (2003) Identification and characterization of G beta 3s2, a novel splice variant of the G-protein beta 3 subunit. Biochem J 371:223-232.
164. Rosskopf D, Schürks M, Rimmbach C, and Schäfers RF (2007) Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol 374:429-469.
165. 3-Adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111:652-673.
166. 3 polymorphism on adrenoceptor-mediated lipolysis in human fat cells. Diabetes 51:1601-1608.
167. 1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol 138:386-392.
168. 1-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 367:10-21.
169. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, and Witteman JC (2003) Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 34:1634-1639.
170. Schäfers RF, Nürnberger J, Rütz A, Siffert W, Wenzel RR, Mitchell A, Philipp T, and Michel MC (2001) Hemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein β3 subunit. Pharmacogenetics 11:461-470.
171. Scharplatz M, Puhan MA, Steurer J, Perna A, and Bachmann LM (2005) Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review. Curr Control Trials Cardiovasc Med 6:16.
172. Schelleman H, Klungel OH, van Duijn CM, Witteman JC, Hofman A, de Boer A, and Stricker BH (2005) Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. Br J Clin Pharmacol 59:483-485.
173. Schelleman H, Klungel OH, Witteman JC, Breteler MM, Yazdanpanah M, Danser AH, Hofman A, van Duijn CM, de Boer A, and Stricker BH (2007) Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 15:478-484.
174. Schürks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, and Rosskopf D (2007) G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 82:396-401.
175. Schwabe U and Paffrath D (2008) Arzneiverordnungsreport 2007, Springer-Verlag, Heidelberg, Germany.
176. Schweiger TA and Zdanowicz MM (2008) Vasopressin-receptor antagonists in heart failure. Am J Health-Syst Pharm 65:807-817.
177. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 359:789-799.
178. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, et al. (2008) Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52:644-651.
179. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, and Tsujimoto G (1996) Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118:1403-1408.
180. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, et al. (2007) Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 99:250-255.
181. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, et al. (1998) Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18:45-48.
182. Siffert W (2005) G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 56:17-28.
183. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, et al. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885.
184. 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275:23059-23064.
185. 2-adrenoceptor polymorphisms. Trends Pharmacol Sci 22:471-477.
186. Small KM, Brown KM, Forbes SL, and Liggett SB (2001) Polymorphic deletion of three intracellular acidic residues of the β2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 276:4917-4922.
187. Small KM, Wagoner LE, Levin AM, Kardia SL, and Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142.
188. Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, and Liggett SB (2004) Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci U S A 101:13020-13025.
189. Small KM, Mialet-Perez J, and Liggett SB (2008) Genetic variation within the beta1-adrenergic receptor gene results in haplotype-specific expression phenotypes. J Cardiovasc Pharmacol 51:106-110.
190. 2-adrenoceptors on haemodynamic responses to adrenaline. Clin Sci 104:509-520.
191. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, Lam CW, Chow CC, Chan WB, Kong AP, et al. (2006) Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Kidney Int 69:1438-1443.
192. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther 73:366-371.
193. 1A-Adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther 75:539-545.
194. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, and Fagard R (1999) M235T angiotensinogen gene polymorphism and cardiovascular risk. J Hypertens 17:9-17.
195. Tabara Y, Kohara K, and Miki T (2002) Polymorphisms of genes encoding components of the sympathetic nervous system but not the renin-angiotensin system as risk factors for orthostatic hypotension. J Hypertens 20:651-656.
196. Talke P, Stapelfeldt C, Lobo E, Brown R, Scheinin M, and Snapir A (2005) Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction. Pharmacogenet Genomics 15:357-363.
197. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, et al. (2005) β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 77:127-137.
198. The Betablocker Evaluation Survival Trial Investigators (2001) A trial of the betablocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667.
199. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, and Starke K (2003) All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol 368:504-512.
200. Tsikouris JP and Peeters MJ (2007) Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease. Cardiovasc Drugs Ther 21:121-132.
201. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, and Liggett SB (1996) Myocardial signaling defects and impaired cardiac function of a human β2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 93:10483-10488.
202. 3- adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374:385-398.
203. Walum H, Westberg L, Henningsson S, Neiderhiser JM, Reiss D, Igl W, Ganiban JM, Spotts EL, Pedersen NL, Eriksson E, et al. (2008) Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci U S A 105:14153-14156.
204. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, Kwon JM, Wu W, Dick DM, Rice J, et al. (2004) Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 13:1903-1911.
205. Weinstein LS, Liu J, Sakamoto A, Xie T, and Chen M (2004) Minireview: GNAS: normal and abnormal functions. Endocrinology 145:5459-5464.
206. Weinstein LS, Chen M, Xie T, and Liu J (2006) Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 27:260-266.
207. Wenzel RR, Siffert W, Bruck H, Philipp T, and Schäfers RF (2002) (2002) Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics 12:489-495.
208. Wettschureck N and Offermanns S (2005) Mammalian G proteins and their cell type specific functions. Physiol Rev 85:1159-1204.
209. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, and Balmforth AJ, and the MERIT-HF Study Group (2003) An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5:463-468.
210. Wilkie MJ, Smith D, Reid IC, Day RK, Matthews K, Wolf CR, Blackwood D, and Smith G (2007) A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 17:207-215.
211. 2-adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority human population. J Hypertens 24:1041-1047.
212. Xie HG, Kim RB, Stein CM, Gainer JV, Brown NJ, and Wood AJ (1999) Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics 9:651-656.
213. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 11:191-197.
214. Yamamoto M, Abe M, Jin JJ, Wu Z, Tabara Y, Mogi M, Kohara K, Miki T, and Nakura J (2004) Association of a GNAS1 gene variant with hypertension and diabetes mellitus. Hypertens Res 27:919-924.
215. Yang W, White B, Spicer EK, Weinstein BL, and Hildebrandt JD (2004) Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 14:741-747.
216. Yasuda K, Matsunaga T, Moritani T, Nishikino M, Gu N, Yoshinaga M, Nagasumi K, Yamamura T, Aoki N, and Tsuda K (2004) T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects. Clin Exp Pharmacol Physiol 31:597-601.
217. Zhang L, Hu A, Yuan H, Cui L, Miao G, Yang X, Wang L, Liu J, Liu X, Wang S, et al. (2008) A missense mutation in the CHRM2 gene is associated with familial dilated cardiomyopathy. Circ Res 102:1426-1432.
218. Zill P, Baghai TC, Zwanzger P, Schüle C, Minov C, Behrens S, Rupprecht R, Möller HJ, Engel R, and Bondy B (2002) Association analysis of a polymorphism in the G-protein stimulatory alpha subunit in patients with major depression. Am J Med Genet 114:530-532.
219. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, and Johnson JA (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536-544.